Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01270139
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:15.892417+00:00
Published At
2012-08-30T00:00:00+00:00
Record Updated At
2021-03-17
Results Posted At
2012-08-30
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Stable Angina", "Heart Failure", "Atherosclerosis", "Multivessel Coronary Artery Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-03-17"
protocolSection.identificationModule.nctId
"NCT01270139"
protocolSection.identificationModule.officialTitle
"Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2012-08-30"

Study condition terms

  • Stable Angina (protocolSection.conditionsModule.conditions)
  • Heart Failure (protocolSection.conditionsModule.conditions)
  • Atherosclerosis (protocolSection.conditionsModule.conditions)
  • Multivessel Coronary Artery Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.